Last reviewed · How we verify
Drug: Placebo Administered SC
Placebo has no active pharmacological mechanism; it is an inert substance used as a control in clinical trials.
At a glance
| Generic name | Drug: Placebo Administered SC |
|---|---|
| Sponsor | BrightGene Bio-Medical Technology Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 3 |
Mechanism of action
Placebo is administered to serve as a comparator arm in randomized controlled trials, allowing researchers to isolate the true therapeutic effect of an investigational drug from placebo response and natural disease progression. The subcutaneous (SC) route of administration matches the delivery method of the active comparator drug being studied.
Approved indications
Common side effects
Key clinical trials
- A Study of Mezagitamab in Adults With Primary IgA Nephropathy Kidney Condition (PHASE3)
- Treatment of Acute Ischemic Stroke (ReMEDy2 Trial) (PHASE2, PHASE3)
- Exenatide for Smoking Cessation and Prevention of Weight Gain (PHASE2)
- Study to Evaluate the Safety and Efficacy of Lenacapavir (GS-6207) in Combination With an Optimized Background Regimen (OBR) in Heavily Treatment Experienced Participants Living With HIV-1 Infection With Multidrug Resistance (PHASE2, PHASE3)
- A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Participants With Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease (PHASE3)
- Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent (PHASE3)
- An Efficacy and Safety Study of NTB003 in Participants With Thyroid Eye Disease (TED) (PHASE1, PHASE2)
- Study of XmAb942 in Healthy Participants and Participants With Ulcerative Colitis (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: